Valuation is grounded on a normalized EV/EBITDA multiple of ~15x applied to the midpoint of 2026E EBITDA ($275M), reflecting strong recurring revenue, margin expansion, and secular growth but discounting for integration and execution risks. Share count reflects the post-Riverpoint equity raise (36.…
Novanta (NOVT) Q2 2026: Riverpoint Medical Adds $65M, Elevates Recurring Revenue to 25%
Novanta’s Q2 2026 marks a pivotal expansion as the $65 million Riverpoint Medical acquisition nearly doubles recurring medical consumables, now 25% of annualized revenue, and accelerates margin and growth trajectories. Strategic manufacturing rationalization and robust automation demand further underpin a raised outlook, with secular tailwinds in AI, robotics, and minimally invasive surgery reinforcing multi-year visibility. Integration execution and operational leverage are now in focus as management targets sustained margin gains into 2027.
Summary
- Recurring Revenue Expansion: Riverpoint Medical acquisition nearly doubles consumables, increasing recurring mix to 25%.
- Margin Leverage from Manufacturing Moves: Site closures and system upgrades drive sequential gross margin gains.
- AI and Robotics Tailwinds: Automation segment growth and design wins reinforce multi-year secular demand strength.
Business Overview
Novanta is a technology solutions provider for medical and advanced industrial markets, generating revenue through engineered components, subsystems, and consumables. Its business is organized into two core segments: Medical Solutions, which supplies OEMs with devices for surgery, diagnostics, and therapy; and Automation Enabling Technology (AET), which delivers laser, robotics, and precision manufacturing solutions. The company’s revenue is split nearly evenly between medical (51%) and advanced industrial (49%) end markets, with a growing focus on recurring consumables and high-growth automation applications.
Performance Analysis
Q2 2026 delivered broad-based organic growth across all business units, with reported growth further boosted by the Riverpoint Medical acquisition. The AET segment outperformed expectations, led by 12% revenue growth and a 450 basis point gross margin expansion, driven by product mix, price discipline, and operational productivity. Medical Solutions grew 8.6% organically, highlighted by a 70% surge in new product revenue within advanced surgery, though gross margin was temporarily diluted by lower-margin precision medicine sales and transformation costs.
Operating cash flow reached $117 million year-to-date, already surpassing the entire prior year, reflecting disciplined working capital management and the benefit of manufacturing moves. R&D intensity scaled down to 9% of sales as new product launches ramped, while SG&A increased due to variable compensation and one-time system investments. The Riverpoint Medical acquisition contributed $35 million in Q3 revenue, with a run-rate EBITDA margin near 40%, and is expected to be immediately accretive to growth, margins, and earnings.
- Automation Segment Margin Inflection: 470 basis point sequential gross margin gain, driven by mix and productivity, signals operating leverage potential.
- Medical Consumables Upshift: Riverpoint Medical acquisition nearly doubles recurring consumable revenue to $300 million, lifting medical exposure to 60% of sales.
- Cash Flow Outperformance: YTD operating cash flow exceeds full-year 2025, supporting M&A and capacity expansion without balance sheet strain.
Management raised full-year guidance, citing accelerating bookings, strong backlog, and integration momentum. The automation segment’s exposure to GenAI and semiconductor demand (now 17% of revenue) grew 25% YoY, with two years of committed backlog in key product lines.
Executive Commentary
"With the close of Riverpoint Medical at the end of July, we're also raising our full year 2026 outlook, positioning Novanta to deliver more than 15% rewarded revenue growth year over year for the full year. Very proud of the performance in our accomplishments, putting us on a solid growth trajectory and a path to exceeding our strategic goals."
Matthijs Glastra, Chair and Chief Executive Officer
"Adjusted EBITDA was $60.7 million, demonstrating more than 16% growth year over year and achieving a nearly 23% adjusted EBITDA margin, which is up 120 basis points versus the prior year. ... Year-to-date operating cash flow was $117 million, which is already exceeding the operating cash flows we delivered for the full year of 2025."
Robert Buckley, Chief Financial Officer
Strategic Positioning
1. Recurring Revenue Acceleration
The Riverpoint Medical acquisition is transformative, nearly doubling Novanta’s recurring medical consumables to $300 million and lifting the recurring mix from 15% to 25% of annualized revenue. This shift enhances revenue visibility and margin stability, while expanding medical market exposure to 60% of total sales.
2. Manufacturing Rationalization and Operational Leverage
Site closures and the establishment of regional Lighthouse Centers of Excellence are central to Novanta’s margin expansion strategy. The company completed two factory closures in Q2 and accelerated plans for two more by Q1 2027, reducing asset intensity and supporting a sequential gross margin step-up to 48% in the back half of 2026.
3. Innovation-Driven Organic Growth
New product revenue grew over 50% in Q2, raising the vitality index (share of sales from new products) to 29%. Design wins and bookings momentum are strong in both segments, with advanced surgery and AI-driven automation platforms driving growth. Bookings rose 18% YTD, and backlog is up 11%, underpinning multi-quarter visibility.
4. Secular Tailwinds in Automation and AI
Automation Enabling Technology is benefiting from durable secular trends in AI, robotics, and semiconductor manufacturing, now representing 17% of total revenue and growing 25% YoY. Orders for humanoid robotics and advanced manufacturing subsystems are moving from prototyping to training and early deployment, with multi-year demand visibility.
5. Capital Allocation and Balance Sheet Strength
Novanta maintains a net cash position even after the Riverpoint acquisition, with a net leverage ratio of negative two times and $719 million in cash. The company raised $300 million in equity to fund the deal, preserving financial flexibility for further investment and capacity expansion, including the doubling of China factory capacity for air bearing spindles.
Key Considerations
This quarter marks a strategic inflection for Novanta, as recurring revenue, operational leverage, and secular tailwinds converge. The integration of Riverpoint Medical and the acceleration of manufacturing rationalization are critical levers for sustaining above-market growth and margin expansion.
Key Considerations:
- Integration Execution: Success in Riverpoint Medical integration and realization of targeted accretion is pivotal for sustaining raised guidance and future margin gains.
- Margin Expansion Path: Site closures, system upgrades, and product mix are expected to drive sequential gross margin improvement to 48% by year-end and into 2027.
- End-Market Diversification: Balanced exposure to medical and advanced industrial markets, with growing AI and semiconductor demand, reduces cyclicality risk.
- New Product Vitality: High vitality index and design win momentum support multi-year organic growth, but require continued R&D discipline and commercialization execution.
- Cash Flow and Capital Deployment: Record operating cash flow and conservative leverage enable continued investment in innovation and capacity expansion without financial strain.
Risks
Integration risk remains elevated as Novanta absorbs its largest acquisition to date, with potential for operational disruption or slower-than-expected synergy capture. Manufacturing rationalization introduces execution risk, as site closures and system migrations could impact near-term productivity or customer delivery. Tariff and supply chain volatility persist, particularly in electronics and rare earths, though management has taken steps to insulate operations. Life sciences remains a drag, with commoditization and near-term decline expected until late 2027.
Forward Outlook
For Q3 2026, Novanta guided to:
- GAAP revenue of $300 million to $304 million (21% to 23% reported growth, 7% to 9% organic growth)
- Adjusted EBITDA of $74 million to $77 million (27% to 33% YoY growth), with a 25% EBITDA margin
- Adjusted diluted EPS of $0.95 to $1.00 (10% to 15% YoY growth)
For full-year 2026, management raised guidance:
- GAAP revenue of $1.13 billion to $1.14 billion (15%+ reported growth, up to 7% organic)
- Adjusted EBITDA of $273 million to $278 million (24% to 26% YoY growth)
- Adjusted EPS of $3.68 to $3.74 (12% to 14% YoY growth)
- Gross margin of 47% for the year, stepping up to 48% in the back half
Management emphasized:
- “Committed backlog, accelerating customer optimism, and solid execution of new product introductions” underpin confidence in raised targets.
- Automation segment to achieve 12% to 14% growth in Q3, with AI and robotics as key drivers.
- Medical Solutions to see 32% to 35% reported growth in Q3, with advanced surgery up ~10%.
- Life sciences exposure to remain below 10% of sales, with growth resuming in late 2027.
Takeaways
Novanta’s strategic pivot toward recurring revenue, operational leverage, and secular automation tailwinds is now in full execution mode, with clear evidence of margin expansion and cash flow outperformance.
- Recurring Revenue and Margin Mix: Riverpoint Medical instantly lifts recurring consumables to 25% of revenue, providing stability and margin accretion that de-risks the growth profile.
- Operational Scale and Execution: Accelerated site closures and system upgrades are delivering sequential margin gains, but require flawless execution to avoid disruption.
- Secular Growth Visibility: AI, robotics, and advanced manufacturing platforms are driving bookings and backlog, with multi-year demand visibility and design win momentum.
Conclusion
Novanta’s Q2 2026 results validate its strategy of scaling recurring revenue, leveraging operational transformation, and capturing secular growth in automation and medical technology. Integration execution, margin realization, and continued innovation will be the critical watchpoints as the company targets sustained outperformance into 2027 and beyond.
Industry Read-Through
Novanta’s results underscore several broader industry signals: The rapid scaling of recurring consumables revenue via M&A highlights the value of predictable, high-margin streams in medtech. Automation and AI-driven manufacturing remain robust secular growth drivers, with design wins and backlog providing multi-year visibility for suppliers of enabling technologies. Operational rationalization and regionalization are increasingly essential for margin expansion and supply chain resilience, especially as tariff and trade risks persist. Industry peers in medtech, automation, and industrial technology should note the strategic premium on recurring revenue, operational leverage, and exposure to AI and robotics infrastructure as key valuation and growth levers for the coming cycle.